Biotech Stocks News 11 December 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)—from Nasdaq-100 index inclusion (effective Dec. 22) to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra (vutrisiran) as

20 December 2025

Analyst Opinions·Biotech Stocks·Financial Forecasts·Investment Analysis·Stock Market News

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest

20 December 2025

Biotech Stocks·FDA Updates·Financial Forecasts·Investment Analysis·Stock Market News

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) finished Friday, December 19, 2025, with shares around $400 and little change in after-hours trading — but the setup into the next U.S. session looks more eventful than the calm “after the bell” tape suggests.

20 December 2025

After Hours Trading·Biotech Stocks·Financial News·Investment Analysis·Stock Market

Wave Life Sciences (WVE) Stock News Today (Dec. 18, 2025): Why Shares Are Sliding, New Analyst Targets, and the Next Catalysts After WVE-007 Obesity Data

Wave Life Sciences Ltd. (NASDAQ: WVE) is back in the spotlight on December 18, 2025—not because of a brand-new press release, but because the stock is still digesting one of the most volatile biotech weeks of the year. In Thursday

18 December 2025

Analyst Ratings·Biotech Stocks·Investment Insights·Stock Market News

Iovance Biotherapeutics (IOVA) Stock News Today (Dec. 18, 2025): Barclays Lifts Target to $10, Analysts Stay Split on Amtagvi’s Launch

December 18, 2025 — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is back in the spotlight after a sharp two-day move that pushed the stock back to the $2.5 area—still far below where many Wall Street price targets sit, but enough to

18 December 2025

Analyst Ratings·Biotech Stocks·Investment Updates·Pharma Industry·Stock Market News

Sarepta Therapeutics (SRPT) Stock: Latest News, Analyst Forecasts, and Key Catalysts to Watch on Dec. 16, 2025

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is back in the spotlight on Tuesday, December 16, 2025—not because the story suddenly got simpler, but because it’s at the intersection of three things the market obsessively prices every day: regulatory risk, clinical evidence,

16 December 2025

Analyst Forecasts·Biotech Stocks·Investment News·Market Analysis·Pharmaceutical Industry

Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is back on traders’ radars on December 16, 2025, after a sharp, high-volume move that has pushed the clinical-stage biotech into “crowded trade” territory—where catalysts, liquidity, and sentiment can matter as much as fundamentals. As

16 December 2025

Analyst Insights·Biotech Stocks·Investment Strategies·Market Trends·Stock Market News

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class”

15 December 2025

Analyst Forecasts·Biotech Stocks·Clinical Trials·Investment Insights·Market News

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences, Inc. (NYSE: RCUS) is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior

14 December 2025

Analyst Ratings·Biotech Stocks·Financial News·Investment Analysis·Stock Market

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences Corp. (NASDAQ: AVXL) is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex (also known as blarcamesine / ANAVEX®2-73) in Alzheimer’s disease—an outcome that investors had been

12 December 2025

Analyst Forecasts·Biotech Stocks·Investment Updates·Pharmaceutical Industry·Stock Market News

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update

12 December 2025

Analyst Ratings·Biotech Stocks·Clinical Trials·Market Updates

Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

As Wall Street digests a fresh Federal Reserve rate cut and growing worries about an AI spending bubble, today’s U.S. stock tape is dominated by dramatic downside moves. From Oracle’s double‑digit plunge to biotech blow‑ups and reverse‑split micro‑caps, December 11,

11 December 2025

AI Technology·Biotech Stocks·Financial News·Investing·Stock Market

Biotech Stocks News 11 December 2025 - 20 December 2025